Pneumonia
636 results
1 - 100
Chest PT not effective for kids with pneumonia- GERD tx in children assoc with pneumonia risk
- Pneumonia vaccine effective in nursing homes
- Oral antiseptics reduce ventilator-associated pneumonia
- Guidelines for pediatric pneumonia from BTS
- Inhaled budesonide for COPD not associated with pneumonia
- Steroids = placebo in community acquired pneumonia
- Fluoroquinolones effective for community-acquired pneumonia
- Pneumonia: 3 days of antibiotics for uncomplicated course
- Lung ultrasound accurate for diagnosis of pneumonia in adults
- Low rate of bacteremia in children hospitalized with pneumonia
- CURB65 rule as accurate as pneumonia severity index
- Pneumonia can be treated with 3 to 5 days of abx
- Inhaled steroids for COPD associated with increased risk of pneumonia
- Clinical signs and symptoms of pneumonia unreliable in children
- In-hospital PPI use associated with hospital-acquired pneumonia
- Urinary antigen test useful for diagnosis of pneumococcal pneumonia
- Serum procalcitonin not very accurate in diagnosing children with pneumonia
- Steroids beneficial as adjunctive treatment for community-acquired pneumonia
- Linezolid no better than vancomycin for treatment of nosocomial pneumonia
- Dexamethasone reduces LOS in patients with community-acquired pneumonia
- Corticosteroids improve outcomes in patients with severe community-acquired pneumonia
- Evidence does not show benefit of treating mycoplasma pneumonia in children
- Inhaled corticosteroids increase pneumonia risk in stable COPD
- Excess treatment with antibiotics for pneumonia is common and may lead to harm
- Three days of amoxicillin is effective for pneumonia with tachypnea in young children
- Net benefit with azithromycin use in elderly hospitalized patients with pneumonia
- Vancomycin plus rifampicin effective in treatment of nosocomial MRSA pneumonia
- Risk of serious pneumonia in COPD patients using inhaled corticosteroids
- Reliability of some clinical exam findings is dubious in children with suspected pneumonia
- More expensive omadacycline no worse than moxifloxacin for community-acquired pneumonia
- Community-acquired pneumonia: Most oral treatments are similarly effective
- Most common identified causes of community-acquired pneumonia are viruses
- Very expensive lefamulin is no worse than moxifloxacin for community-acquired pneumonia
- Procalcitonin rules out pneumonia in patients with dyspnea in the emergency department
- Lung ultrasound reduces need for CXR in children with suspected pneumonia
- Fluticasone + salmeterol may reduce mortality but also increase pneumonia in COPD
- Implementation of 3-step pathway reduces LOS for hospitalized pneumonia patients
- Three-day course of inhaled amikacin is effective in preventing ventilator-associated pneumonia
- Overuse alert: Prophylactic abx don't prevent poststroke pneumonia in patients with dysphagia
- Useful signs and symptoms for diagnosing pneumonia in children younger than 5 years
- Shorter courses of antibiotics for community-acquired pneumonia at least as good as longer courses
- Systemic corticosteroids reduce need for ICU or mechanical ventilation in patients with community-acquired pneumonia
- Inappropriate diagnosis of community-acquired pneumonia in hospitalized patients is common among older adults
- No improvement in clinical status at 28 days with tocilizumab in patients with severe COVID-19 pneumonia
- Decreased risk of mechanical ventilation with tocilizumab for treatment of moderate to severe COVID-19 pneumonia
- C-reactive protein is the most useful biomarker for diagnosis of outpatient community-acquired pneumonia
- Scores based on bedside clinical findings are helpful in identifying pneumonia in febrile children
- Intravenous hydrocortisone reduces all-cause mortality in severe community-acquired pneumonia (CAPE COD)
- Daily (or more frequent) toothbrushing is associated with lower rates of hospital-acquired pneumonia in ICU patients
- Convalescent plasma does not improve outcomes in patients hospitalized with severe COVID-19 pneumonia (PlasmAr)
- Fewer exacerbations but somewhat more pneumonia with triple inhaler therapy for COPD (IMPACT)
- Lower risk of early ventilator-associated pneumonia with antibiotics in patients with out-of-hospital cardiac arrest
- Five days of antibiotic therapy is comparable with 10 days in children with community-acquired pneumonia (SAFER)
- Combination of baricitinib and remdesivir reduces recovery time in patients hospitalized with COVID-19 pneumonia
- Early tracheotomy ineffective at preventing ventilator-associated pneumonia in mechanically ventilated ICU patients
- Tofacitinib reduces composite outcome of death or respiratory failure in patients with COVID-19 pneumonia (NNT = 9)
- Comparable outcomes with 5 days and 10 days of antibiotics in children with community-acquired pneumonia (SCOUT-CAP)
- Fewer new clots using high-dose prophylactic anticoagulation for patients with hypoxemic COVID-19 pneumonia (ANTICOVID)
- Updated guidelines from the Society of Critical Care Medicine strongly recommend steroids for hospitalized adults with severe community-acquired pneumonia